Experts are predicting demand for life-saving antiviral drugs will rapidly outpace supply. Like the vaccine, the poorest countries will be left until last

Covid-19 has quietly become the gift that keeps on giving for big pharma. The past two years has seen it reap huge profits from Covid vaccines, while simultaneously opposing wider sharing of the technology required to make them. And now there’s a new money-spinner on the rise: Covid antiviral treatment pills. Once again, we’re poised to fall into the same inequality traps we’re caught in with the global vaccine rollout.

Both Pfizer and Merck have new antiviral pills rapidly arriving on the market – Paxlovid and molnupiravir respectively. As with the vaccines that came before them, both corporations have made it their business to ultimately decide who gets to make generic versions through the medical patent system – a crucial, life-saving question for millions around the world.

Othoman Mellouk is a medicine access advocate with the International Treatment Preparedness Coalition

Continue reading…

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Andy Murray and Novak Djokovic ready to cross swords after five-year gap

Veteran pair meet in third round of Madrid Open Dan Evans and…

Australia live news update: Novak Djokovic fights to overturn visa cancellation in federal court as Victoria records 13 Covid deaths

Serbian tennis star’s challenge to immigration minister Alex Hawke’s decision to deport…

Poor countries to be offered extra funding to break Cop26 impasse

Climate finance plan needed to gain backing of developing nations for any…